Tag:
Schering-Plough
Latest Headlines
Latest Headlines
Merck tracks positive results, bleeding risk in second big vorapaxar study
Merck says that vorapaxar , its troubled blood thinner once considered the jewel in Schering-Plough's crown when the pharma giant bought it for $41 billion, hit its primary efficacy endpoint in a
Feds subpoena Merck in marketing probe
Merck has stumbled into one of the hidden traps of megamergers. The Department of Justice is probing the marketing of three drugs inherited from Schering-Plough, Merck disclosed to the SEC in a
S-P sales reps win another OT round
Chalk up another victory for sales reps in their fight for overtime pay. A U.S. judge has decided that Schering-Plough sales people don't qualify for the administrative exemption under U.S. labor
Merck to re-invest in scaled-back Irish plant
This is what you call taking away with one hand while giving with the other. Merck says it's planning to invest €29 million ($41.8 million) at its plant in Cork, Ireland, and create 70 jobs
Schering Plough $473M IRS ruling holds
The U.S. Court of Appeals in Philadelphia has upheld an IRS ruling against Schering Plough, which leaves Merck with a $473 million IRS bill. The case stemmed from an interest rate swap with two of
Ex-CRO workers alleged to have falsified data in Schering study
Federal prosecutors are alleging that two people formerly with a CRO in Kansas falsified data in an early-stage study done on behalf of Schering-Plough (which merged with Merck in 2009), the Kansas
Sanofi eyes cost cuts and deals for vet unit
In the wake of its decision to abandon an animal-health joint venture with Merck, Sanofi is revamping its strategy for its vet business. As Sanofi fully integrates Merial, the animal-health unit it
Merck to pay J&J $500M in Remicade settlement
Merck ( $MRK ) can breathe a bit easier now that arbitrators have determined the fates of Remicade and Simponi, the arthritis drugs the drugmaker co-markets with Johnson & Johnson ( $JNJ ). With
Merck feels pain of Schering ops integration
Difficulties integrating the manufacturing and supply chain operations of two big pharma companies is crimping the supply of women's health products. As Merck continues to swallow Schering-Plough
Analysts reassess Merck-Schering merger
The judgment of Merck's Schering-Plough merger hangs in the balance, analysts tell Reuters. If the company loses big in its negotiations over the rights to Remicade and its follow-up drug Simponi,
